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1. INTRODUCTION 
Dicyclomine HCl is mainly used as antispasmodic and 
antiulcer drug. This is mainly anticholinergic. The drug 
is used in sever spasm of stomach in stomach pain. 
Dicyclomine HCl is bitter in taste so the drug is prepared 
with the use of ion exchange resin to mask the taste of 
active drug. The drug is given as an oral tablet is rapidly 
and well absorbed from the gastrointestinal tract after 
oral administration. The absolute bioavailability is 
approximately 70% with no substantial loss by first pass 
metabolism A 500 mg oral dose given every 12 hrs has 
been shown to produce an area under the serum 
concentration time curve(AUC) equivalent to that 
produced by an intravenous infusion of 400mg is given 
over 60min every 12hrs. 
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Figure 1: Structural formula of Dicyclomine HCl 
Novel drug delivery technologies are revolutionizing 
drug discovery and development. The challenge in the 
area of drug delivery is to deliver both existing and 
emerging drug technologies in a manner that benefits 
patients. 
Good mouth feel of formulation helps to change the 
basic view of medication from “bitter pill” to “better 
pill”. Taste is one of the most important parameters 
governing patient compliance. Undesirable taste is one of 
several important formulation problems that is 
encountered with certain drugs. Oral administration of 
bitter drugs with an acceptable degree of palatability is a 
key issue for health care providers, especially for 
pediatric patients. Also, such pharmaceutical 
preparations used for elderly patients have been 
investigated to improve the treatment compliance and 
quality of life of such patients. Thus, the problem of 
bitter and obnoxious taste of drug in pediatric and 
geriatric formulations is a challenge to the pharmacist in 
the present scenario. 
Patient expects the oral dosage form to be pleasantly 
flavored and palatable. This change in patient attitude is 
due to the advances made by flavoring and 
pharmaceutical industries. Several oral pharmaceuticals 
and bulking agents have unpleasant, bitter‐tasting 
components. Thus, any pharmaceutical formulation with 
a pleasant taste would definitely be preferred over 
another product and would translate into better patient 
compliance and therapeutic value. The desire of 
improved palatability in these products has prompted the 
development of numerous formulations with improved 
aesthetic appearance and performance. 
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The application of drug delivery technology to any 
molecule is based on market needs, product 
differentiation, and patient compliance. The time to get 
the new chemical entity to the market eats up a majority 
of the patent life cycle of the drug. Taste masking 
technologies are very helpful in adding value/timeline to 
the patent.
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2. MATERIALS AND METHODS 
2.1 Materials: 
Dicyclomine HCl was gift sample from Sun Pharma 
Ltd., (Jammu, India). Tulsion 335 and Indion 254 was 
obtained as gift sample from Corel Pharma Chem, 
(Ahmedabad, India). Indion 414 purchased from Ion 
exchange India limited (Mumbai, India). Sucrose, 
sorbitol, glycerine, xanthane gum, aspartame, methyl 
paraben and mango candy flavour were purchased from 
S. D. Fine chemicals (Mumbai, India). All other 
chemicals/solvents were of analytical grade. 
2.2 Methodology: 
2.2.1 Purification of ion exchange resin 
Resins were purified using the method reported by Irwin 
et al.12. The resins (5 g) were washed successively with 
distilled water, methanol (50 ml), benzene (50 ml), 
methanol (50 ml) and several times with distilled water 
to eliminate organic and color impurities. Then, the wet 
resins were activated by 0.1 M HCl 50 ml and washed 
several times with distilled water. All resins were dried 
overnight in hot air oven at 500C and kept in an amber 
glass vial. 
2.2.2 Preparation of drug – resin complex 
Drug-resin complex were prepared by batch process. 
Step 1: Weigh all the ingredient accurately. Now add 
weighted quantity of resin in specific quantity of water 
and stir it for 15 min. under mechanical stirrer. Step 2: 
Now add weighted quantity of Dicyclomine HCl  into 
step 1 & stir it for 4 to 5 hr. continuously under stirrer. 
Step 3: Take specific quantity of water boil it dissolve 
sugar & filter it. Now cool the syrup at room temperature 
and add sorbitol and glycerin in it & add into step 2 
under continuous stirring13, 14, 15. Step 4: Take water & 
add xanthane gum and stir it to form a paste. Add this 
paste in step 3 slowly under stirring. Step 5: Take warm 
water dissolve methylparaben, propylparaben & 
aspartame in to it & add in to above solution under 
stirring. Step 6: Now add coloring, flavoring agent in 
step 5 & make volume of suspension up to required 
quantity by using purified water, pH of resin solution 
was adjusted to 8 by using 1 M KOH16. 
 
Table 1: Formulation of Dicyclomine HCl suspension with different resins 
Ingredients D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 
Complex formation  
Dicyclomine HCl [mg] 500 500 500 500 500 500 500 500 500 500 
Tulsion 335 300 600 900 - - - - - - - 
Indion 254 - - 300   300 600 - -  
Indion 414 - - - - - - - 300 600 900 
Purified water 25 25 25 25 25 25 25 25 25 25 
Surup preparation  
Sucrose [gm] 2.25 2.25 2.25 2.25 2.25 2.25 2.25 2.25 2.25 2.25 
Glycerin [ml] 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Xanthan gum [mg] 20 20 20 20 20 20 20 20 20 20 
Methyl paraben [mg] 10 10 10 10 10 10 10 10 10 10 
Propyl paraben [mg] 4 4 4 4 4 4 4 4 4 4 
Aspartame [mg] 15 15 15 15 15 15 15 15 15 15 
Mango candy flavor  0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 
Quinoline yellow color 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Purified water [ml] 5 5 5 5 5 5 5 5 5 5 
 
2.2.3. Evaluation of taste masked suspension 
(a) Determination of drug content in resonates: 
Dicyclomine HCl resinate (50 mg) was placed in a 
beaker to which 0.1N HCl (50 ml) was added for eluting 
Dicyclomine HCl from the resinate17. The volume of 
eluate was measured and assayed for the content of 
Dicyclomine HCl by spectrophotometry at wavelength of 
272 nm. 
 (b) In-vitro release of suspension: 
Dissolution studies of above samples were performed 
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using USP XXIII apparatus type 2. Suspension 
equivalent to 400 mg of the drug were added to the 
dissolution medium (500 ml 0.1N HCl at a temperature 
of 37 0C ± 0.50C), which was stirred with a rotating 
paddle at 50 rpm18. At suitable time intervals, 10 ml 
samples were withdrawn, filtered (0.22 µm), diluted and 
analyzed at 272 nm using UV spectrophotometer 
(c) Determination of Viscosity: 
The viscosity of gel was determined at ambient condition 
(DV III+, Brookfield Programmable Rheometer) using 
adequate amount of the sample19. 
(d) Taste Evaluation: 
The taste of suspension was checked by panel method. 
The study protocol was explained and written consent 
was obtained from volunteers. For this purpose, 10 
human volunteers were selected17. About 5 ml 
suspension containing 500 mg of drug was placed on 
tongue and taste evaluated after 15 s. Take 10 ml of 
suspension in 100 ml volumetric flask & make up the 
volume up to 100 ml with 0.1N HCl. Now take 2 ml 
solution from flask & add in to 200 ml volumetric flask. 
Make up the volume up to 200 ml with 0.1 N HCL filter 
it & measure the absorbance at wavelength 277 nm in 
U.V. Spectrophotometer & compare it with standard. 
Calculate % drug content by using following formula. 
(f) Sedimentation volume: 
Sedimentation volume (F) is a ratio of the final or 
ultimate volume of sediment (Hu) to the original volume 
of sediment (H0) before settling. It can be calculated by 
following equation.   
 
𝐹 =  
𝐻𝑢
𝐻𝑜
 ------------- (1) 
      Where, Hu = final or ultimate volume of sediment 
H0 = original volume of suspension before settling. 
(g) Accelerated Stability Study: 
Suspensions were packed in 60 ml glass bottle. The 
packed bottles were placed in stability chamber 
maintained at 40 + 2 oC and 75 + 5% RH for 3 month. 
Samples were collected at days 0, 5, 15, 30, 60 and 90. 
The analyses comprised chemical testing of quantifiable 
parameters, which could possibly change during storage, 
such as viscosity, pH, drug contents, sedimentation 
volume, redispersibility, taste and any kind of microbial 
or fungal growth14, 20. 
3. RESULT AND DISCUSSION 
         For preparation of resinates, batch method was 
preferred because of its convenience. Equilibrium was 
reached within 6 h. The high affinity of resins to 
hydrogen ions can yield fast desorption of bound ions 
when they are exposed to an acidic environment such as 
the stomach. When the pH is lower than 4, the resin 
exists in the Free State. Therefore, drug/resin complex 
formation needs to be carried out at pH 6 or higher. 
Higher concentration of competing ions at 
lower pH may inhibit the interaction of resins21. At pH 8 
maximum loading of Dicyclomine HCl was seen onto 
Tulsion 335, Indion 254 and Indion 414 (data not 
shown). Effect of drug: resin ratio on % drug content per 
gram of resinate are shown in [Table 2]. It shows that for 
Tulsion 335 and Indion 254 maximum drug loading were 
observed at 1:2 drug resin ratio while 1:1 was observed 
for indion 414. As the cross linking ratio and particle size 
increased, the drug loading and release rate decreased 
due to the reduced effective diffusion coefficient and 
surface area. When the resin is highly cross linked, fewer 
functional groups are available inside the particle, 
resulting in low ion-exchange capacity 22, 23. 
 
 Table 2: Evalution parameter of Dicyclomine HCl suspension with different resins 
Parameters D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 
Drug loading of 
dry resinate 
- 32.15 41.46 42.28 39.42 43.95 46.42 39.58 38.45 43.25 
Color Pale  Pale  Pale  Pale  Pale  Pale  Pale  Pale  Pale  Pale  
Viscosity 298.2 296.58 302.45 304.23 296.25 304.58 300.52 297.42 304.2 306. 
pH 7.8 8 7.6 8 7.9 7.5 8.1 7.8 7.8 8 
Sedimentation 
volume 
0.98 0.97 0.95 0.97 0.98 0.96 0.92 0.95 0.93 0.96 
Redispersibility ++ ++ +++ ++ ++ +++ +++ ++ ++ ++ 
Assay  99.47 100.02 99.75 99.88 100.65 99.58 99.98 98.96 100.1 99.87 
 
Results of taste evaluation by panel method [Table 3] revealed that Tulsion 335,  Indion 254 and Indion 414 mask the 
bitter taste of drug completely at 1:2 and 1:2.5 ratios.  
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Table 3: Evaluation of taste of suspension 
Code  Volunteers 
1 2.  3.  4.  5.  6.  7.  8.  9.  10.  
C1 3 2 3 3 2 3 3 2 3 3 
C2 2 2 3 1 0 2 1 0 3 1 
C3 1 2 0 1 0 3 2 1 2 0 
C4 0 1 0 2 3 1 2 1 3 0 
C5 20 1 3 2 1 0 1 3 2 2 
C6 1 2 0 1 2 1 3 2 0 1 
C7 0 3 1 2 3 0 2 1 2 3 
C8 2 0 2 1 2 1 2 3 1 0 
C9 1 2 1 3 1 2 1 0 2 1 
C10 2 1 2 0 3 2 1 0 3 2 
0 = normal, 1 = slightly bitter, 2 = bitter, 3 = very bitter 
 
In vitro release profile of resinates prepared using 
different resins is shown in [Figure 2]. Study was carried 
out in 0.1 N HCL using USP paddle apparatus at 50 rpm. 
More than 80% of drug was released within 30 min from 
C7 formulation. In general, strong acid type resins 
showed greater sustained release than weak acid type 
resins in in vitro dissolution tests 17, 24. In general, drug is 
released from the resinate by exchanging with ions in a 
surrounding release medium, followed by drug diffusion 
through the polymer matrix of the resinates. Some drug 
molecules released accumulated around the surface of 
the resinates to form an aqueous boundary layer. Stirring 
can be introduced to the diminish this layer. However, 
higher cross linked resins display a more sustained 
release effect than lower cross linked resins. Slight 
distinction between release profile of formulations may 
be due to various cross linking ratio of resins.
 
 
Figure 2: In vitro dissolution profile of D7 (Dicyclomine HCl-Indion 254, 46.3% drug loading) 
 
Accelerated stability study of C7 is shown in [Table 4]. Study revealed that prepared formulation (C7) can be 
remaining intact for a long period of time without major changes in assay, viscosity and sedimentation volume. It was 
found that formulation was remained palatable without any appearance of microbial growth in agar plates. 
 
Table 4: Accelerated stability study of D7 
Parameters Time periods 
Initial one day One month Two month Three month 
Assay % 100.42 99.85 99.35 99.23 
Viscosity 335.54 334.25 333.52 334.54 
pH 7.8 7.7 7.7 7.65 
Sedimentation 
volume 
0.97 0.96 0.96 0.95 
Redespersibility +++ +++ +++ +++ 
Taste  Palatable  Palatable  Palatable  Palatable  
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4. CONCLUSION 
Use of weak cation exchange resin offers superior 
method for preaparing taste-masked substrates of 
Dicyclomine HCl. A result obtained in this work shows 
that drug-resin complexes effectively masked bitter taste 
of Dicyclomine HCl. While liquid formulation provides 
easier way to administer and getting the child to 
swallow. Also to overcome problem with non 
compliance with child especially around 8 years old for 
whom swallowing other dosage form can be challenging. 
Thus, the “patient-friendly dosage form” of bitter drugs, 
especially for pediatric, geriatric, bedridden, and non 
cooperative patients, can be successfully formulated 
using this technology. 
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